{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "TVTX",
  "name": "Travere Therapeutics, Inc.",
  "url": "https://frontierpicks.com/dossiers/TVTX/",
  "json_url": "https://frontierpicks.com/dossiers/TVTX.json",
  "status": "DORMANT",
  "current_conviction": "MEDIUM",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Q2 beat on 2026-08-04 ($169.6M revenue vs $159.6M consensus; FILSPARI US sales +96% YoY to $141.1M) re-opened sell-side headroom — six target raises 08-05→08-10 into a $70–85 band while the 2026-08-14 close of $62.14 sits 1.0% under the 52wk high. The ramp narrative is accelerating, but the next dated resolver is the early-November Q3 print, with only the Sept 8–10 conference block in between.",
  "invalidation_trigger": "A weekly close below $55 gives back the 2026-08-05 post-print gap and puts price under the July range (07-07 close $57.85, 07-17 close $56.71). Secondary: a Q3 print with new patient start forms below the 2,012 booked in Q2, or the Sept 8–10 conference block passing with no reclaim of the $62.76 high.",
  "catalyst_date": "2026-09-08",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "rare-disease-gene-therapy",
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Q3 2026 results estimated early November; no company-confirmed date as of 2026-08-14 — verify the dated IR release before assuming the window.",
    "$525M of 0.50% convertible notes due 2032 (closed 2026-05-11) convert at ~$64.90/share, a reference sitting just above the 2026-08-14 close of $62.14.",
    "No full-year 2026 revenue guidance was disclosed in the 2026-08-04 Q2 release; Street models are not anchored to a company-set number.",
    "FSGS has no approved competitor; IgAN — the larger revenue base — competes with Novartis Fabhalta and Vera Therapeutics' atacicept.",
    "Ligand (LGND) carries a sparsentan royalty, so its royalty line is a separate read on FILSPARI unit demand.",
    "Company reports GAAP and non-GAAP EPS that diverge widely: Q2 2026 was $(0.37) GAAP vs $(0.10) adjusted."
  ],
  "body_markdown": "## Current Thesis\nThe July frame — approval binary spent, price sitting inside the target band, no sell-side headroom left — resolved on 2026-08-04. Q2 2026 revenue came in at $169.584M against a $159.589M consensus, adjusted EPS at $(0.10) against $(0.14), and the stock traded up more than 13% after hours. Six target raises followed inside four sessions: Citi to $85 and Evercore to $68 on 08-05, TD Cowen and Guggenheim to $75 on 08-05, Wedbush to $75 and Canaccord to $70 on 08-06, then Evercore again to $78 on 08-10. The 2026-08-14 close of $62.14 is 1.0% under the 52-week high of $62.76 and below every one of those marks. The leg an investor is buying is no longer a regulatory binary but a commercial ramp: FILSPARI US net product sales of $141.1M in Q2, +96% YoY, on 2,012 new patient start forms, across two indications of which FSGS has no approved competitor. What the next 30 days do not contain is anything that resolves it — three investor conferences and then a wait until the early-November print.\n\n## Bull Case\n- **The ramp accelerated rather than plateaued.** FILSPARI US net product sales $141.1M in Q2 2026, +96% YoY; first-half 2026 sales $246.2M, +93% YoY (2026-08-04 Q2 release). Total US net product sales of $161.4M compare with $94.8M in Q2 2025.\n- **Demand is measured in patients, not just dollars.** 2,012 new patient start forms received in Q2 2026 — the disclosure that separates price/reimbursement effects from underlying prescriber adoption, and the number a Q3 print grades directly.\n- **Revenue beat the Street on the first full FSGS-contributing quarter.** $169.584M reported vs $159.589M consensus; the FSGS indication received full FDA approval on 2026-04-14 as the first approved therapy for FSGS without nephrotic syndrome.\n- **The re-rating band moved up, not just the price.** Post-print targets cluster at $70–$85 (Citi $85, Evercore $78 on 08-10, TD Cowen $75, Wedbush $75, Guggenheim $75, Canaccord $70) versus the $52–58 consensus range that bracketed spot through July.\n- **Balance sheet funds the launch.** $489.2M cash and equivalents at 2026-06-30, following the 2026-05-11 close of $525M in 0.50% convertible senior notes due 2032 (≈$508.5M net proceeds) used to refinance the 2029 notes — the maturity wall moved out and the coupon dropped.\n- **Pipeline optionality was bought with cash, not equity.** The civorebrutinib in-license from Everest Medicines closed in July 2026 with a $112.5M upfront payment. Chugai submitted a sparsentan NDA in Japan in June 2026, adding an ex-US royalty path.\n\n## Bear Case\n- **Still GAAP loss-making, and the loss widened.** Q2 2026 net loss $34.8M ($0.37 per basic share) versus $12.8M ($0.14) in Q2 2025, on Q2 SG&A of $96.1M and R&D of $60.3M. The adjusted $(0.10) headline is $25.8M of add-backs away from the reported number.\n- **No company-set bar.** The 2026-08-04 release disclosed no full-year 2026 revenue guidance. Street models carry the ramp with nothing from management anchoring them, which removes the guidance-raise mechanism that usually extends a launch re-rating between prints.\n- **The mark-up wave for this cycle has already been spent.** Six raises landed between 08-05 and 08-10. There is no second sell-side revision cohort scheduled before Q3 results.\n- **IgAN — the larger revenue base — is contested.** Novartis's Fabhalta and Vera Therapeutics' atacicept compete for the same nephrology prescriber. FSGS is the uncontested layer; headline FILSPARI totals blend the two, so a competitive share shift shows up late.\n- **Conversion overhang sits immediately overhead.** The 2032 notes convert at approximately $64.90 per share, about 4.4% above the 2026-08-14 close of $62.14 — a reference the equity has to clear and hold before the converts stop acting as a supply-side ceiling.\n- **The bridge to the next pipeline datapoint is long.** Pegtibatinase HARMONY Phase 3 topline is guided to 2H 2027. Nothing in the clinical portfolio prints inside 2026.\n\n## Setup & Price Structure\nThe narrative is **accelerating**, dated by the 2026-08-04 print, the 2026-08-05 gap higher, and the 08-05→08-10 target cluster into $70–$85. This is the third mark-up wave on the same story (April approval, mid-June, August print), which makes the label fragile rather than wrong: a Q3 print with start forms below the 2,012 booked in Q2, with no further target revisions, would put it in maturing.\n\nObservables on crowding and positioning, stated without a verdict:\n- The 2026-08-14 close of $62.14 is 1.0% below the 52-week high of $62.76; the three-month return is +45.9% and RSI(14) reads 64.5. Price is extended against its own base but not at a momentum extreme.\n- Retail-facing coverage clustered tightly around the event (\"TVTX Stock Rallies Over 13% After Hours\", 2026-08-05) rather than spreading through the following week.\n- The company issued $525M of converts on 2026-05-11 at a ~$64.90 conversion price, roughly 15% above where the stock traded through mid-July — issuance into strength, executed as a refinancing of the 2029 notes rather than as new equity.\n- No earnings date falls inside the next 30 days. The catalyst gap runs from the September conference block to the early-November print.\n\nThe structure that matters: the 2026-08-05 gap is unfilled and the July range (07-07 close $57.85, 07-17 close $56.71) sits beneath it as the first shelf. A weekly close under that range is what would show the post-print re-rating round-tripping.\n\n## Catalyst Calendar (next 30 days)\n- **2026-09-08** — Wells Fargo 21st Annual Healthcare Conference presentation. First management commentary since the Q2 call; watch for any framing of Q3 start-form trajectory.\n- **2026-09-09** — Citi 2026 Biopharma Back to School Conference. Citi carries the high mark at $85 (2026-08-05); its own conference is where that model gets defended or softened.\n- **2026-09-10, 9:10 a.m. ET** — 2026 Cantor Global Healthcare Conference presentation.\n- **~2026-11-03 (est.)** — Q3 2026 results. Outside the 30-day window and the only event that grades the ramp; no company-confirmed date as of 2026-08-14.\n\n## What Would Change Our Mind\nThe structural break is the 2026-08-05 gap failing to hold. Price giving back the whole post-print move and closing back inside the July range would say the Q2 beat bought a re-rating the tape would not keep — concretely, a weekly close below $55, which sits under both the 07-07 close of $57.85 and the 07-17 close of $56.71.\n\nOn fundamentals, the number that would flip the read is the Q3 new patient start-form count. Q2 booked 2,012; a Q3 figure below that, with FILSPARI sequential growth decelerating, would mean the FSGS layer is a one-quarter step-up rather than a second growth curve — and would make the $70–$85 target band a set of stale marks.\n\nThe third condition is time. If the September 8–10 conference block passes with no incremental disclosure and price has not reclaimed the $62.76 high, the name becomes a two-month wait on a story where the sell-side revision cycle is already complete.\n\n## Correlation Notes\n- **LGND (Ligand Pharmaceuticals)** holds a sparsentan royalty. Its royalty line is an independent, separately-audited read on FILSPARI units and moves on the same commercial datapoint.\n- **NVS (Novartis, Fabhalta) and VERA (atacicept)** are the competitive reads on the IgAN base. Their nephrology disclosures matter more to the TVTX revenue mix than headline FILSPARI totals do.\n- **XBI / IBB** — a company with a $34.8M GAAP quarterly loss and $489.2M of cash carries small/mid-cap biotech beta into rate moves and sector risk-appetite swings regardless of its own ramp.\n- **Chugai/Roche** — the June 2026 Japanese NDA submission makes ex-US regulatory timing a partner-controlled variable rather than a Travere-controlled one.",
  "first_seen": "2026-04-19",
  "last_analyzed": "2026-08-15T12:18:20+00:00",
  "last_synthesized": "2026-08-15",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}